Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector
CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and r...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1519055/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841540158963318784 |
|---|---|
| author | Huanhuan Zhou Wenxiang Zhu Qihong Ma Ning Liu Mengdi Jin Yaru Feng Lijun Zhao Rui Sun Rongyou Li Huaxiu Li Yuanyuan Shi Jianxun Wang Liqiong Liu Zhi Guo Zhi Guo Zhi Guo |
| author_facet | Huanhuan Zhou Wenxiang Zhu Qihong Ma Ning Liu Mengdi Jin Yaru Feng Lijun Zhao Rui Sun Rongyou Li Huaxiu Li Yuanyuan Shi Jianxun Wang Liqiong Liu Zhi Guo Zhi Guo Zhi Guo |
| author_sort | Huanhuan Zhou |
| collection | DOAJ |
| description | CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and refractoriness after multiple lines of high-intensity chemotherapy. After physician evaluation, this patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT). Then, The patient remained in complete remission (CR) for four months before a relapse with 26.64% chimerism rate, so he was treated with allogeneic anti-CD7 CAR-T cells after chemotherapy reducing the tumor burden. The CAR-T product was a novel anti-CD7 CAR-T based on retroviral vectors (RV). After infusion, the patient achieved CR within 1 month after anti-CD7 CAR-T infusion and the remission has been ongoing for 9 months to date. Cytokine release syndrome (CRS) 1 was experienced while no immune effector cell-associated neurotoxicity syndrome (ICANS) was found. In addition, CAR copy number peaked at 350, 758 copies/μg on day 6. This case report of clinical treatment of T-ALL with anti-CD7 CAR-T cells prepared using a retroviral vector without gene editing and combined with chemotherapy, which demonstrated that the RV-based anti-CD7 CAR-T cells had good therapeutic effect and high safety in triple-refractory T-ALL patients. |
| format | Article |
| id | doaj-art-e8fba2b4a7a944719e8b5cb0b3c3c1f7 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-e8fba2b4a7a944719e8b5cb0b3c3c1f72025-01-14T06:10:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15190551519055Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vectorHuanhuan Zhou0Wenxiang Zhu1Qihong Ma2Ning Liu3Mengdi Jin4Yaru Feng5Lijun Zhao6Rui Sun7Rongyou Li8Huaxiu Li9Yuanyuan Shi10Jianxun Wang11Liqiong Liu12Zhi Guo13Zhi Guo14Zhi Guo15Department of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, ChinaNanozyme Laboratory in Zhongyuan, Henan Academy of Innovations in Medical Science, Zhengzhou, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, ChinaDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaShenzhen Cell Valley Biomedical Co., LTD, Shenzhen, ChinaDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, ChinaDepartment of Hematology, The Sixth Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, ChinaNational Health Commission (NHC) Key Laboratory of Nuclear Technology Medical Transformation (Mianyang Central Hospital), Mianyang, ChinaInstitute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, ChinaCD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). In this study, we reported a case of a 34-year-old male patient with T-ALL who finally developed multi-line drug resistance and refractoriness after multiple lines of high-intensity chemotherapy. After physician evaluation, this patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT). Then, The patient remained in complete remission (CR) for four months before a relapse with 26.64% chimerism rate, so he was treated with allogeneic anti-CD7 CAR-T cells after chemotherapy reducing the tumor burden. The CAR-T product was a novel anti-CD7 CAR-T based on retroviral vectors (RV). After infusion, the patient achieved CR within 1 month after anti-CD7 CAR-T infusion and the remission has been ongoing for 9 months to date. Cytokine release syndrome (CRS) 1 was experienced while no immune effector cell-associated neurotoxicity syndrome (ICANS) was found. In addition, CAR copy number peaked at 350, 758 copies/μg on day 6. This case report of clinical treatment of T-ALL with anti-CD7 CAR-T cells prepared using a retroviral vector without gene editing and combined with chemotherapy, which demonstrated that the RV-based anti-CD7 CAR-T cells had good therapeutic effect and high safety in triple-refractory T-ALL patients.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1519055/fullT-ALLCD7 CAR-Tchemotherapyretroviral vectorscomplete remission |
| spellingShingle | Huanhuan Zhou Wenxiang Zhu Qihong Ma Ning Liu Mengdi Jin Yaru Feng Lijun Zhao Rui Sun Rongyou Li Huaxiu Li Yuanyuan Shi Jianxun Wang Liqiong Liu Zhi Guo Zhi Guo Zhi Guo Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector Frontiers in Immunology T-ALL CD7 CAR-T chemotherapy retroviral vectors complete remission |
| title | Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector |
| title_full | Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector |
| title_fullStr | Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector |
| title_full_unstemmed | Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector |
| title_short | Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector |
| title_sort | case report the case of t cell acute lymphoblastic leukemia treated with chemotherapy followed by anti cd7 car t cells using retroviral vector |
| topic | T-ALL CD7 CAR-T chemotherapy retroviral vectors complete remission |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1519055/full |
| work_keys_str_mv | AT huanhuanzhou casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT wenxiangzhu casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT qihongma casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT ningliu casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT mengdijin casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT yarufeng casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT lijunzhao casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT ruisun casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT rongyouli casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT huaxiuli casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT yuanyuanshi casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT jianxunwang casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT liqiongliu casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT zhiguo casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT zhiguo casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector AT zhiguo casereportthecaseoftcellacutelymphoblasticleukemiatreatedwithchemotherapyfollowedbyanticd7cartcellsusingretroviralvector |